



OPEN ACCESS

APPROVED BY
Frontiers in Editorial Office,
Frontiers Media SA, Switzerland

*CORRESPONDENCE
Kejing Wang,
wymwkj001@163.com
Lin Chen,
cqfycl@126.com
Yang Yang,
cqfyy2020@163.com

SPECIALTY SECTION
This article was submitted to
Pharmacology of Anti-Cancer Drugs,
a section of the journal
Frontiers in Pharmacology

RECEIVED 09 July 2022
ACCEPTED 11 July 2022
PUBLISHED 11 August 2022

CITATION
Zhao Q, Ma P, Fu P, Wang J, Wang K,
Chen L and Yang Y (2022),
Corrigendum: Myelodysplastic
syndrome/acute myeloid leukemia
following the use of poly-ADP ribose
polymerase inhibitors: A real-world
analysis of postmarketing
surveillance data.
Front. Pharmacol. 13:990048.
doi: 10.3389/fphar.2022.990048

COPYRIGHT
© 2022 Zhao, Ma, Fu, Wang, Wang,
Chen and Yang. This is an open-access
article distributed under the terms of the
[Creative Commons Attribution License
\(CC BY\)](#). The use, distribution or
reproduction in other forums is
permitted, provided the original
author(s) and the copyright owner(s) are
credited and that the original
publication in this journal is cited, in
accordance with accepted academic
practice. No use, distribution or
reproduction is permitted which does
not comply with these terms.

Corrigendum: Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data

Quanfeng Zhao¹, Pan Ma¹, Peishu Fu¹, Jiayu Wang^{2,3},
Kejing Wang^{2,3*}, Lin Chen^{2,3*} and Yang Yang^{2,3*}

¹Department of Pharmacy, The First Affiliated Hospital of Third Military Medical University (Army Medical University), Chongqing, China, ²Department of Pharmacy, Women and Children's Hospital of Chongqing Medical University, Chongqing, China, ³Department of Pharmacy, Chongqing Health Center for Women and Children, Chongqing, China

KEYWORDS

PARP inhibitors, myelodysplastic syndrome, acute myeloid leukemia, pharmacovigilance, real-world

A Corrigendum on Myelodysplastic syndrome/acute myeloid leukemia following the use of poly-ADP ribose polymerase inhibitors: A real-world analysis of postmarketing surveillance data

by Zhao, Q., Ma, P., Fu, P., Wang, J., Wang, K., Chen, L., and Yang, Y. (2022). *Front. Pharmacol.* 13:912256. doi: 10.3389/fphar.2022.912256

Text Correction

In the original article, there was an error. Several result values were written incorrectly in the article's abstract. The corrected **abstract** appears below:

In total, 16,710 and 11,937 PARP inhibitor AE reports were found in the FAERS and EV databases, of which 332 and 349 were associated with MDS and AML, respectively. The median latencies of MDS and AML associated with PARP inhibitors were 211 [interquartile range (IQR) 93.5–491.25] days and 355 (IQR 72.00–483.50) days, respectively. The average fatality rates of MDS and AML caused by the four PARP inhibitors were **39.23 and 45.39%**, respectively, in the FAERS database, while those in the EV database were **32.32 and 34.94%**, respectively. Based on the criteria used for the three

algorithms, a significant disproportionate association was found between PARP inhibitors as a drug class and MDS/AML. Notably, the risk of MDS was much higher than that of AML. Olaparib appeared to have a stronger association with MDS and AML than did other PARP inhibitors.

The authors apologize for this error and state that this does not change the scientific conclusions of the article in any way. The original article has been updated.

Publisher's note

All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.